WGI-2101 – MyMiR
WGI-2101 is an anti-microRNA therapy targeting the well-documented microRNA-21 pathway in cancer. Early animal studies have suggested the potent activity of WGI-0301 in suppressing tumor progression and metastatic potential in non-small cell lung cancer.
It is provided as a frozen lipid suspension, which is thawed prior to intravenous injection. It leverages QTsome delivery technology for the efficient loading and delivery of AM-21 to cancer cells. MicroRNA-21 (miR-21) is a well-validated and overexpressed target microRNA in cancer and participates in the regulation of the central pathways of cancer cell proliferation, disease progression, metastasis, and drug resistance. The size of QTsome lipid nanoparticles allows for passive targeting to tumors and highly fenestrated tissues. As the lung contain a vast network of capillary beds, many QTsome may accumulate in cancerous cells of the lung. After uptake in cancer cells by endocytosis, acidic conditions within the endosomal compartment of cells causes disruption of the endosome and release of drug into the cytoplasm where it can bind to miR-21 and inhibit its bioactivity.